版本:
中国

BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint

Sept 15 Merck & Co Inc

* Merck and pfizer announce investigational Ertugliflozin met primary endpoint of A1C reduction when added to Sitagliptin and Metformin in people with type 2 diabetes

* Merck and Pfizer plan to submit NDA for ertugliflozin, two fixed-dose combinations (Ertugliflozin plus Januvia and Ertugliflozin plus metformin) by end of 2016

* Additional regulatory submissions outside of to happen in 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐